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ORIGINAL ARTICLE
Systems Pharmacology Approach for Prediction
of Pulmonary and Systemic Pharmacokinetics and
Receptor Occupancy of Inhaled Drugs
E Boger1,2*, N Evans2, M Chappell2, A Lundqvist1, P Ewing1, A Wigenborg1 and M Friden1,3
Pulmonary drug disposition after inhalation is complex involving mechanisms, such as regional drug deposition, dissolution,
and mucociliary clearance. This study aimed to develop a systems pharmacology approach to mechanistically describe lung
disposition in rats and thereby provide an integrated understanding of the system. When drug- and formulation-specific
properties for the poorly soluble drug fluticasone propionate were fed into the model, it proved predictive of the
pharmacokinetics and receptor occupancy after intravenous administration and nose-only inhalation. As the model clearly
distinguishes among drug-specific, formulation-specific, and system-specific properties, it was possible to identify key
determinants of pulmonary selectivity of receptor occupancy of inhaled drugs: slow particle dissolution and slow drug-
receptor dissociation. Hence, it enables assessment of factors for lung targeting, including molecular properties, formulation,
as well as the physiology of the animal species, thereby providing a general framework for rational drug design and facilitated
translation of lung targeting from animal to man.
CPT Pharmacometrics Syst. Pharmacol. (2016) 5, 201–210; doi:10.1002/psp4.12074; published online 14 April 2016.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?  Several drug and formulation properties are held as indi-
vidually effective for achieving lung-selectivity. However, simple empirical inhalation PK-models do not allow for evaluation
of the net effect of property combinations or for translation of inhaled drug pharmacology. • WHAT QUESTION DID THIS
STUDY ADDRESS?  What combinations of drug and formulation properties result in lung-selective receptor occupancy,
given the physiology of the test species?. • WHAT THIS STUDY ADDS TO OUR KNOWLEDGE  A mechanistic inhala-
tion PK-model was developed and is made available. This model can guide the design of compounds and inhaled drug
formulations with optimal local pharmacology and provide a logic framework for translation of inhaled drug pharmacology.
Specific findings in this study include lung-selectivity possibly being unattainable in the well-perfused parts of the lung
and that slow drug-receptor dissociation can be a drug property providing lung-selectivity. • HOW THIS MIGHT CHANGE
CLINICAL PHARMACOLOGY AND THERAPEUTICS  The model can be used in clinical studies to tailor inhaled drug
formulations, target appropriate dose ranges, and interpret study results.
Inhalation is an attractive route of administration that has
been used for more than 2,000 years.1 The capability of
delivering drug directly to the target organ has been associ-
ated with advantages, such as a rapid onset of action and
a higher and more sustained local tissue concentration.2
The latter offers an opportunity to increase the therapeutic
index by achieving lung-selectivity and thus fulfilling the aim
of locally acting inhaled drugs (i.e., to obtain high concen-
trations at the lung target site while the systemic concentra-
tions are kept at a minimum).3 In order to minimize the
systemic exposure, and thus systemic side effects, drug
discovery typically aims to develop inhaled drugs with high
hepatic clearance to obtain a rapid elimination and to avoid
absorption from the gastrointestinal tract.4
Nevertheless, achieving lung-selectivity after inhalation is
not a trivial task. The large surface area, good vascularization,
and thin alveolar epithelium offer the potential for rapid absorp-
tion into the systemic circulation.5 Indeed, with the exception
of i.v. administration, inhalation is the fastest route for systemic
drug delivery of small molecules. This is particularly prominent
for small lipophilic molecules, in which the absorption half-life
is 1–2 minutes.6 Several strategies for enhancing lung reten-
tion have therefore been explored, including increasing basic-
ity,7 formulation approaches8 and low solubility.9
However, assessment of lung-selectivity has so far pro-
ven to be elusive. Collection of relevant exposure measure-
ments is recognized as a challenge both within clinical and
preclinical research. Because the appearance of drug in
the systemic circulation is the result of pulmonary absorp-
tion, unbound concentrations in plasma cannot be assumed
to reflect the target site concentration in the lung.2 This
constitutes a challenge because unbound plasma concen-
trations usually form the basis for establishing pharmacoki-
netic/pharmacodynamic (PK/PD) relationships.
In a preclinical setting, lungs can be collected by destruc-
tive sampling at several time points after intratracheal
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administration or dry powder inhalation. Drug concentrations
are subsequently measured in lung tissue homogenates,
providing a time profile of total lung concentrations in which
the organ is erroneously reflected as one anatomic entity.
Moreover, the homogenization process severely distorts the
data interpretation by disrupting the normal compartmentali-
zation (e.g., lysosomal trapping) and by dissolving solid drug
particles.10 Indeed, the establishment of PK/PD relationships
based on total lung concentrations is known to be more
challenging for poorly soluble compounds.7 As receptor
occupancy is driven by the unbound drug concentration at
the target site, such measurements could clarify the PK after
topical administration. A methodology capable of in vivo
receptor occupancy measurements in the lung and in a ref-
erence organ for systemic exposure has therefore been
developed.11 By applying this method, further understanding
can be gained as comparison of pulmonary and systemic
occupancies provides a quantitative readout of the degree of
lung-selectivity achieved by inhalation.
Even so, interpretation of data from preclinical PK studies
can be challenging. Rodents are generally exposed via
nose-only inhalation, in which a substantial deposition of
drug particles will occur in the nose.10 Drug deposited in
the lung and the nose will both be subject to the self-
cleansing mechanism mucociliary clearance (MCC), which
transports drug particles toward the pharynx where they
are eventually swallowed.12 Accordingly, the resulting
plasma PK is a result of parallel absorption from the lung,
the nose, and the gastrointestinal tract.13,14
Hence, despite the historical success and widespread
use of locally acting inhaled drugs, pulmonary drug disposi-
tion remains poorly understood. It is recognized as complex
because several important processes take place simultane-
ously, such as regional drug deposition, dissolution of solid
drug particles and MCC. Additional complexity comes from
the heterogeneous nature of the organ with distinct differen-
ces between the tracheobronchial and alveolar regions.9 An
integrated understanding, which takes the mechanistic
processes as well as the organ heterogeneity into account,
is thus desirable.
Simulation models have previously been used to predict the
systemic exposure for inhaled corticosteroids in humans.
Weber and Hochhaus15 developed a compartmental simula-
tion tool, in which the lung was divided into two subcompart-
ments representing the central and peripheral region,
respectively. The model also included features, such as MCC
and drug dissolution, described by rate constants.15 Earlier
simulations, using an even simpler model structure with one
lung compartment and receptor binding described by a static
model, showed that slow drug dissolution gives lung-selectiv-
ity.16 Chaudhuri et al.17 used GastroPlus to predict the sys-
temic PK of budesonide. The simulated plasma profiles of
both models proved to agree well with experimental data.
Nevertheless, a mechanistic model predictive of local tissue
concentrations combined with measurements such as recep-
tor occupancy for validation is currently lacking. Such a model
would be necessary to elucidate the highly complex processes
involved in pulmonary drug disposition.18
This study aimed to develop a physiologically based
pharmacokinetic model including lung disposition for rats,
which can integrate the current knowledge of the system
with drug- and formulation-specific properties. The model
puts emphasis on lung disposition by mathematically
describing both the physiology and the fate of the deposited
dose. When drug- and formulation-specific input parame-
ters for the poorly soluble drug fluticasone propionate (FP)
were fed into the model, it accurately predicted the PK both
after i.v. administration as well as via nose-only inhalation.
It was also possible to predict target site exposure, as vali-
dated by receptor occupancy measurements. Because this
approach allows for separation between drug- and system-
specific properties, it will aid in understanding which drug-
and/or formulation-specific properties are associated with
lung-selectivity and thus yield favorable efficacy/safety pro-
files for inhaled drugs. Moreover, because the parametriza-
tion of this model is based on the physiology of the animal,
it provides a framework for a facilitated translation by
switching to human system-specific properties.
METHODS
Experiments
Please refer to the Supplementary Material for experimen-
tal details about the PK and the receptor occupancy studies.
PK study. The PK of FP was studied in rats after i.v. admin-
istration of 90 and 1,000 nmol/kg (n5 2 and n5 3, respec-
tively). Blood samples were repeatedly collected from a
venous catheter for 8 hours after administration.
Receptor occupancy studies. The time course of glucocorti-
coid receptor occupancy and the PK was studied in rats
after nose-only inhalation (lung deposited dose [LDD]:
11.3 nmol/kg) and i.v. administration of FP (90 nmol/kg),
the latter study as well as a detailed experimental protocol
are described in a previous study.11 The inhalation study
was performed twice using the same experimental setup.
Model development
This section gives an overview of the model. Detailed
descriptions of the model, its different subcomponents, and
the mathematical derivations are included in the Supple-
mentary Material.
Model structure. A mechanistic physiologically based phar-
macokinetic model (PBPK) including lung disposition was
implemented in MATLAB R2013a (Mathworks, Natick, MA).
The structural model is illustrated in Figure 1a. Blood flows
and volumes of the tissue compartments included are pre-
sented in Table 1.
The lung was divided into a tracheobronchial and alveolar
region; each of these was in turn divided into three sepa-
rate compartments (Figure 1b). The same compartmental
representation was used for the nose: (1) solid drug (Asolid);
(2) dissolved drug in the epithelial or nasal lining fluid
(Cfluid); and (3) drug in tissue (Ctissue). The tracheobronchial
region is perfused by the bronchial blood flow (Qbr), the
alveolar region by the entire cardiac output (QCO), and the
nose by the nasal blood flow (Qn).
Perfusion-rate limited distribution was assumed to apply
for all tissues. For compartment i, the rate of change of
quantity within the organ can be described as24:
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Vi
dCiðtÞ
dt
5Qi CAðtÞ2RCiðtÞKp;i
 
; Cið0Þ50; (1)
where Vi is the tissue volume, Ci is the drug tissue concen-
tration, Qi is the blood flow to the tissue, CA is the arterial
drug concentration, R is the blood/plasma ratio, and Kp,i is
the tissue-plasma partition coefficient.
Particle size distribution and regional deposition. The parti-
cle size distribution was determined using an impactor, pro-
viding a discrete distribution consisting of eight particle size
classes. The mass fractions (f1,. . .,f8) are presented in
Table 2 and experimental details in the Supplementary
Material.
Inhaled drug particles can be deposited in the extrathora-
cic, tracheobronchial, and alveolar region. This model
neglects deposition in the pharynx, hence only nasal depo-
sition is considered in the extrathoracic region. Henceforth,
the tracheobronchial and alveolar regions are referred to as
the central and peripheral lung, respectively.
Several models have been developed for the prediction of
regional particle deposition in rat lungs.25–28 By using deposi-
tion fractions for the relevant aerodynamic diameters
extracted from ref. 25 and the mass fractions for the corre-
sponding particle size classes, the number of deposited par-
ticles of size class i in region j (Nj,i) can be calculated. As
specified in the Supplementary Material, Nj,i is used for sim-
ulating drug dissolution and total amount of solid drug.
Mucociliary clearance. Because of MCC, Nj,i was modeled
as an exponential decay:
Nj ;iðtÞ5Nj ;ið0Þ3e2kmcc;j t ; (2)
where Nj,i(0) is the number of particles of size class i in
region j at t50 and kmcc,j is MCC in region j. MCC in the
central lung (kmcc,lung) was estimated from ref. 29 as
described in the Supplementary Material and MCC in the
nose (kmcc,nasal) was extracted from ref. 30; the rate con-
stants are presented in Table 3. MCC in the peripheral
lung was assumed to be negligible, since it is primarily
associated with the tracheobronchial region.34 Conse-
quently, Nj,i in the peripheral region is constant. Drug
removed by MCC is transported to the gut, where the bioa-
vailable fraction (F) subsequently can be absorbed into the
systemic circulation. F is defined as:
F5fgut3fabs3fh : (3)
That is, F accounts for the fraction absorbed from the
gastrointestinal tract (fabs), the fraction that escapes the gut
(fgut), and hepatic extraction (fh).
35 Because of the high
blood clearance (CLb), fh was set to 0.
Dissolution of drug. Drug particles are dissolved in the epi-
thelial lining fluid or in the nasal lining fluid. The dissolution
process is modeled by the Nernst–Brunner equation,36,37
Figure 1 (a) Structure of the whole-body physiologically based pharmacokinetic (PBPK) model, and (b) compartmental representation
of the central lung, peripheral lung, and the nose: solid drug (Asolid), dissolved drug in the epithelial or nasal lining fluid (Cfluid), and
drug in tissue (Ctissue). In the nose and the central lung, solid particles are transported by mucociliary clearance (kmcc). Drug particles
are dissolved in the lining fluid (1), once dissolved the drug may permeate through the epithelial membrane to the tissue (2).
Table 1 System-specific input parameters for the rat.
Tissue Volume (fraction of BW) Blood flow (fraction of QCO)
Adipose 0.040a 0.009217a
Gut 0.0259b 0.14b
Liver 0.04c 0.024b
Lung 0.004127d 0.021b/1
Nose 0.000254e 0.0015f
Poorly perfusedg 1-(the rest) 1-(the rest)
Richly perfusedh 0.039c 0.5096c
Spleen 0.002b 0.0715i
Arterial blood 0.02c NA
Venous blood 0.04c NA
NA, not available.
aQCO5 cardiac output, 20.77 L/h/kg ref. 19;
bRef. 20; cRef. 21; dInternal
AstraZeneca data, han Wistar (n5100); eSupplementary Material Eq. S52;
fRef 22; gPoorly perfused5 1 – other organs; hRichly perfused5 richly perfu-
sed1brain1 kidney from ref. 19; iRef 23.
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describing how the dissolution rate depends on the solubil-
ity of the drug (Cs), the concentration in the dissolution
medium, the diffusion coefficient (D), and the surface area
of the particle (4prj,i(t)
2). Detailed descriptions of both the
dissolution and calculation of D35 are provided in the
Supplementary Material.
Detailed description of the lung and nose. The compart-
mental representation of the nose and the two lung regions
is shown in Figure 1b. The system-specific input parame-
ters for the nose and lung are summarized in Table 3.
Once the drug has dissolved (Supplementary Material
Eq. S33) it may permeate to the tissue according to:
dJ
dt
5PAsurf ðCfluid ðtÞfu;fluid2CiðtÞKp;u;i Þ; (4)
where dJ/dt is the molar flow of drug (nmol/h), P is the per-
meability, Asurf is the surface area, Ci is the tissue concen-
tration of drug, and Kp,u,i is the tissue-to-unbound plasma
partition coefficient. A detailed description of the prediction
of Kp,u-values as well as the subsequent calculations of
Kp-values are provided in the Supplementary Material, all
Kp-values are presented in Table 4. The in vitro apparent
permeability across CaCo2-monolayers was measured and
used as P (Table 2).
Receptor binding. Receptor binding was included in all tis-
sue compartments and was described as:
dRDðtÞ
dt
5 Kon Bmax2RDðtÞð ÞCiðtÞKp;u;i
 
2Koff RDðtÞ; (5)
where RD is the concentration of the drug-receptor com-
plex, Kon is the association rate constant, Bmax is the recep-
tor density, and Koff is the dissociation rate constant.
Bmax for the spleen was 31.5 nM,
40 Bmax for the lung was
set to 21 nM,11 and Bmax in the other tissue compartments
was set to the mean value of Bmax over five brain regions
(23 nM).41
Parameterization of the model
Drug-specific input parameters. All drug-specific input
parameters are specified in Tables 2 and 4. The blood/
plasma ratio (R) was used for calculating CLB from the
plasma clearance (CLP) obtained from the PK-study
(Supplementary Material Eq. S21). As CLP was esti-
mated from venous drug concentrations, elimination was
set to occur from the venous compartment. Accordingly,
CLB acts on the absorbed drug prior to entering the
organs.
Parameter estimation. Cs was estimated using nonlinear
least squares in the MATLAB curve-fitting toolbox, in which
Table 2 Drug- and formulation-specific input parameters for fluticasone
propionate
Parameter Value
Blood/plasma ratio 0.95
CLB (L/h/kg) 11.53
CLP (L/h/kg) 10.95
Cs (nM) 4530
Diffusion coefficient (m2/s) 2.27*10211
f1,. . .,f8
a 0.17, 0.30, 0.26, 0.18, 0.073,
0.0091, 0.0032, 0.0035
Fb 0
fu 0.016
fu,fluid 1
Kd (nM) 0.0156 0.0045
Koff (h
21) 0.516 0.17
Kon (L/nmol/h) 346 20
logD7.4 4.2
Molecular weight (g/mol) 500.6
Papp (cm/s) 46.9*10
26
Particle density (nmol/dm3) 1.430*109
r1,. . .,r8 (mm) 3.55, 2.31, 1.42, 0.887,
0.544, 0.349, 0.231, 0.118
Vdss (L/kg) 12.5
Vu,lung (mL/g lung tissue) 213.4
CLB5 blood clearance;CLP5 plasma clearance; Cs5 solubility; f1,. . .,f85mass
fractions for particle size classes 1,. . .,8; F5oral bioavailability; fabs5 fraction
absorbed; fgut5 fraction escaping gut metabolism; fh5 fraction escaping hepatic
metabolism; fu5 fraction unbound in plasma; fu,fluid5 fraction unbound in epithe-
lial or nasal lining fluid; Kd5dissociation constant; Koff5 dissociation rate con-
stant; Kon5association rate constant; Papp5 apparent permeability;
r1,. . .,r85 initial geometric radius for particle size classes 1,. . .,8; Vd,ss5 volume
of distribution at steady state; Vu,lung5 unbound lung volume of distribution.
aP8
i51 fi51 when all decimal places are used.;
bF5fabs*fgut*fh.
Table 3 System-specific input parameters for the central lung, peripheral
lung, and the nose
Parameter Central lung Peripheral lung Nose
Blood flow (fraction of QCO) 0.021
a 1 0.0015b
Surface area (dm2/kg) 3.27c 276.4d 0.416e
Lining fluid volume (mL/kg) 163.6* 193.5* 20.8*
Fraction of tissue volume 0.19* 0.81* NA
kmcc (h
21) 0.0472f NA 0.2079
kmcc, rate constant for mucociliary clearance; NA, not available; QCO, cardiac
output.
*Calculations of the lining fluid volume and tissue fractions are provided in
the Supplementary Material; References: a) Ref. 21; b) Ref. 22; c) Ref. 31
(normalized per kg); d) Ref. 32 (normalized per kg); e) Ref. 33 (normalized
per kg); f) Ref 30.
Table 4 Tissue-plasma partition coefficients (Kp) for tissues included in the
model
Tissue Kp,i Method
Liver 10.2 in silicoa
Spleen 5.18 in silicoa
Richly perfusedb 9.27 in silicoa
Poorly perfusedc 7.70 in silicoa
Gut 20.3 in silicoa
Adipose 126 in silicoa
Lung 3.41 Vu,lung
d
Nose 3.41 Vu,lung
d
aRef. 38.
bKp,richly is the mean value of the predicted Kp-values of the heart and
kidney.
cKp,poorly is the mean value of the predicted Kp-values of bone and muscle.
dRef. 39.
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the Levenberg–Marquardt algorithm minimized the differ-
ence between observed and predicted total lung concentra-
tions (11.3 nmol/kg, LDD). The initial estimate had been
selected from an exhaustive search, in which the sum of
squares was initially evaluated using a broad search space
(102Cs105 nM). The search space was then confined to
the proximity of the best solution Cs,0 (Cs,02200Cs
Cs,01200 nM), in which 300 candidates were evaluated.
With the exception of Cs, all input parameters in the
PBPK model are from literature sources, internal AstraZe-
neca data, or parameter estimates obtained from modeling
of the PK and glucocorticoid receptor occupancy studies as
specified.
Characterization of binding kinetics. Modeling of the binding
kinetics is described in detail in the Supplementary
Material.
Model validation and verification
Administrations via the i.v. route (20, 90, 150, 750, and
1,000 nmol/kg) and via nose-only inhalation (11.3 and
100 nmol/kg, LDD) were simulated using drug-specific input
parameters for FP (Tables 2 and 4). Neither particle size
distribution nor density was available for the higher LDD, it
was therefore assumed to have the same formulation-
specific properties as the lower dose. The simulations were
subsequently compared with experimental data obtained
from this study, AstraZeneca’s internal database, or ref. 11.
Evaluation of concepts for lung-selectivity
In this article, lung-selectivity is defined as the difference
between pulmonary (ROlung) and systemic receptor occupancy
(spleen,ROsp) i.e., the criteria of lung-selectivity is met when:
ROlung2ROsp > 0: (6)
Because the lung is divided into a central and a peripheral
region, lung-selectivity can be evaluated for each region
individually. Besides, the whole lung can also be considered
by using a weighted average based on the occupancy for
the two regions (ROave; Supplementary Material
Eq. S51). Because the experimental methodology cannot
discriminate between central and peripheral occupancy,
ROave corresponds to the observations.
The impact of the following drug-specific input parame-
ters on lung-selectivity was evaluated: CL, F, Cs, and Koff.
Furthermore, one formulation- and one system-specific
input parameter were each investigated: particle size and
Qn, respectively. The contribution of nasal absorption was
evaluated by comparing the systemic PK profile from a
base-case scenario (input parameters from Tables 1–4) to
a scenario in which Qn was set to 0. The particle size distri-
bution was investigated by comparing the base-case sce-
nario to one in which the particles were evenly distributed
between the four smallest size classes, that is fi5 0.25 for
i5 5,. . .,8 and fi5 0 otherwise. In all simulations, LDD was
fixed at 11.3 nmol/kg.
Statistics and data presentation
Monte Carlo simulations were used for receptor occupancy
simulations to account for the uncertainty in the estimated
binding kinetics parameters. Random parameter values for
Kd and Koff were generated from a lognormal distribution
based on the parameter precision obtained from the model-
ing. A large number of simulations (n5 1,000) were made
and 90% confidence intervals were constructed.
Receptor occupancy measurements are presented as
mean6 one SE. As described in the Supplementary Mate-
rial, receptor occupancy was calculated using the ratio
method42 and propagation of error was used for the calcu-
lation of SE.
Sensitivity analysis was performed to investigate how the
dynamic behavior of the system responded to changes in
selected input parameters (Supplementary Figure S5a,b).
RESULTS
Characterization of binding kinetics
Kon and Koff were estimated to be 346 20 nM
21h21 and
0.516 0.17 h21 (Supplementary Figure S1b). An exhaus-
tive search algorithm confirmed that the global minimum
had been found within the defined parameter space.
Model verification and validation
I.V. administration. Model predictions of the plasma profiles
as well as the time course of occupancy (Figure 2a,b)
were consistent with experimental i.v. data (90 and
1,000 nmol/kg). The predicted occupancy profiles in the
two lung regions and the spleen were identical. No occu-
pancy measurements were available for the higher dose.
Regardless of the route of administration, inclusion of the
receptor-bound concentration was essential for the predic-
tive capability of spleen concentrations (Figure 2c).
The model was predictive of receptor occupancy meas-
urements made 1.5 hours after three i.v. doses of FP.
Simulated occupancies were 27%, 64%, and 86% for 20,
150, and 750 nmol/kg, respectively. Simulations agreed
well with observed data: 276 9.7, 746 5.0, and
10063.5% for 20, 150, and 750 nmol/kg, respectively.
Nose-only inhalation. Following estimation of Cs (95% confi-
dence interval54,530 [3,845–5,215] nM), total spleen, lung
and plasma concentrations were well-predicted by the
model after nose-only inhalation (Figure 2c–e). An under-
prediction was noted for the last time point of the higher
dose.
Model predictions of the systemic occupancy were con-
sistent with the observations (Figure 2f). ROave captured
key trends in the data, although a tendency toward under-
prediction was noted (Figure 2g). Neither plasma concen-
trations nor receptor occupancy had been measured
following inhalation of the higher dose.
Evaluation of concepts for lung-selectivity. It was noted that
lung-selectivity could not be achieved if the peripheral lung
was considered as the pulmonary region. That is, no differ-
ence was obtained between the occupancy in the periph-
eral lung and the spleen in this model. Therefore, the
occupancy in the central lung (ROC) is used as the pulmo-
nary region for evaluation of lung-selectivity.
As can be seen in Figure 3a, a longer period of lung-
selectivity was obtained for a poorly soluble drug (Cs5 2.5 mM)
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Figure 2 Simulations and observations of: (a) plasma concentrations (Cp) after i.v. administration of 90 (blue line) and 1,000 nmol/kg (red
line), (b) receptor occupancy in the spleen/peripheral lung/central lung after i.v. administration of 90 nmol/kg (blue line), (c) spleen con-
centration (Cspleen) after i.v. administration of 90 nmol/kg (red line) and after inhalation of a lung deposited dose (LDD) of 11.3 nmol/kg
(blue line). The dashed lines show Cspleen excluding the receptor-bound concentration (d) total lung concentrations after an LDD of
11.3 nmol/kg (blue line) and 100 nmol/kg (red line), (e) Cp after a LDD of 11.3 nmol/kg (blue line), (f) receptor occupancy in the spleen
(ROsp) after an LDD of 11.3 nmol/kg (red line), (g) whole lung receptor occupancy (ROave) after an LDD of 11.3 nmol/kg (blue line), and
(h) receptor occupancy in the central lung (ROc), ROave, and ROsp after an LDD of 11.3 nmol/kg (green, blue, and red line, respectively).
For each receptor occupancy simulation, a 90% confidence interval was created by a Monte Carlo simulation, which repeatedly sampled
random values from a lognormal distribution of the binding kinetics parameters (n51,000, dashed lines). DPI, dry powder inhalation.
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than for a highly soluble drug (Cs550 mM). A transient concen-
tration gradient created during dissolution of a highly soluble
compound (Cs550 mM) could also give rise to a prolonged
lung-selectivity given a slow Koff (Figure 3b).
Given a certain LDD, simulations showed that the particle
size distribution had an impact on the occupancy profile as
well as the degree of lung-selectivity (Figure 3c).
Simulations showed a negative correlation between F
and lung-selectivity, whereas a positive correlation was
found for CL (simulations not shown).
According to the simulations, nasal absorption signifi-
cantly contributed to the systemic exposure and decreased
the degree of lung-selectivity following nose-only inhalation
of FP (Figure 3d,e). Noteworthy is that the nasally depos-
ited dose was predicted to be several-fold higher than LDD
(Supplementary Figure S6).
DISCUSSION
This article presents a systems pharmacology approach for
prediction of systemic and pulmonary PK for inhaled drugs,
which was validated by experimental measurements of drug
concentrations and receptor occupancy. By virtue of being
Figure 3 The impact of different drug-, formulation-, and system-specific properties on lung-selectivity was evaluated by varying the fol-
lowing parameters: (a) solubility; Cs52.5 mM (red line) and 50 mM (blue line), (b) dissociation rate; t1=2,Koff57.5 h (blue line) and 0.3 h
(red line), (c) particle size distribution; f1,. . .,f8 from Table 2 (blue line) and fi50.25 for i55, . . ., 8 and fi50 otherwise (red line), (d)
nasal absorption; nose included (blue line) and nose excluded (red line), and e) nasal absorption; nose included (blue line) and nose
excluded (red line). Except for subfigure e) which shows predictions (lines) and observations (open circles) of plasma concentrations of
fluticasone propionate (Cp), dashed lines represent receptor occupancy in the central lung and solid lines represent occupancy in a
systemic reference organ.
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mechanistic, this model provides a tool to theoretically
explore pulmonary drug disposition and how key processes
in a physiological context produce lung-selectivity.
Data generated from i.v. dosing as well as inhalation
were used for validation, which thus allows the model to
be used to compare the two administration routes. Model
predictions of i.v. administrations were consistent with
experimental data (Figure 2a–c), supporting a perfusion-
rate limited distribution. Notably, input parameters (CL,
Vd,ss, Kon, and Koff) obtained from the modeling of one
dataset (90 nmol/kg, i.v.) proved predictive of data from
four other i.v. dose levels, thus offering strong support and
confidence in its predictive capability to determine sys-
temic PK and receptor occupancy. Interestingly, inclusion
of receptor binding was necessary for accurate predictions
of spleen concentrations (Figure 2c), which verifies that
FP has a high receptor-bound fraction.11 This elucidates
the potential pitfall of only relying on Kp-values when
predicting tissue concentrations after low doses of highly
potent compounds. Under such circumstances, underpre-
dictions are inevitable as Kp-values do not account for
receptor binding.
As the aqueous solubility of poorly soluble compounds
tends to underpredict the in vivo dissolution rate,43 the sin-
gle parameter Cs was estimated from observations of total
drug concentrations in the lung made in one inhalation
study (11.3 nmol/kg, LDD). It is worth noting that the esti-
mate of Cs (4,530 nM) was close to the measured FaSSIF-
solubility (3,120 nM). When the optimized model was tested
on another dataset (100 nmol/kg, LDD), it was shown to be
predictive of the total lung concentrations with the exception
of the last time point (Figure 2d). This could be explained
by either inaccurately described particle size distribution or
limitations of the Nernst–Brunner equation for the alveoli
where the epithelial lining fluid layer might be smaller than
the particle diameter.
Model predictions of plasma concentrations and systemic
occupancy after nose-only inhalation agreed well with
experimental data (Figure 2e,f). This consistency confirms
that FP has a dissolution rate-limited absorption and
emphasizes the importance of mechanistically describing
the dissolution process for such compounds.
Validation of lung occupancy simulations was slightly
more complex as these measurements reflect whole lung
occupancy. Thus, for comparison of observations and
simulations, a weighted average accounting for the rela-
tive contribution of each region was needed. Although
exact determination of the tissue fractions cannot be
made, the volume fraction of the central lung (fv,c) was
approximated to be 0.19 (Supplementary Material).
Given the uncertainty in fv,c and the slightly lower accu-
racy of lung occupancy measurements, a whole lung
occupancy prediction that qualitatively captures key fea-
tures, including lung-selectivity and late occupancy peak
(Figure 2g), can be regarded as a good description of
the data.
For validation purposes, emphasis was not put on
explaining the variability in the data, which is partly caused
by the use of destructive sampling (one animal/time point).
Apart from interindividual differences in model input param-
eters, a high variation in LDD is expected from preclinical
studies. The validation instead focused on how well the
model captured key features in the observations, both on a
quantitative and a qualitative level.
The model was used to provide mechanistic insight into
pulmonary drug disposition and to identify key determinants
for lung-selectivity. As expected, simulations confirmed the
current dogma that inhaled drugs benefit from a high CL and
a low F. A previously unforeseen result was that lung-
selectivity could not be achieved in the peripheral lung. This
is attributed to the high perfusion rate of this region, which
thus rapidly equilibrates with the systemic circulation. In fact,
the model predicted the tissue distribution half-life of FP in
the peripheral lung to be below 2 seconds. However, lung-
selectivity could be obtained in the central region after inhala-
tion as its lower perfusion-rate allows for a longer equilibra-
tion time.
It was shown that a concentration gradient, and thus
lung-selectivity, was obtained during the dissolution phase
(Figure 3a). As expected, the model described the risk of
only obtaining transient lung-selectivity for a rapidly dissolv-
ing drug without any additional mechanisms enhancing its
lung-retention (i.e., a scenario resembling i.v. administration
in which no lung-selectivity is obtained). Nevertheless, a
transient concentration gradient can give rise to an
extended period of lung-selectivity provided that the drug
receptor dissociation rate is relatively slow (Figure 3b).
The latter feature was unforeseen by earlier models
because the receptor binding was described by a static
Emax-model.
16 Accordingly, two mechanisms were found to
be good strategies for achieving lung-selectivity: (1) slow
dissolution; and (2) slow drug receptor dissociation. Nota-
bly, at the other end of the spectrum are low affinity com-
pounds for which a low Cs might disrupt the opportunity of
obtaining sufficiently high target site concentrations to elicit
a pharmacological response. Hence, several drug-specific
properties need to be considered during lead compound
optimization and the presented model is indeed useful for
such exercises.
Simulations verified that the particle size distribution also
has an impact on the dissolution rate and can thus be used
to partly control this process (Figure 3c). Moreover, particle
size is well-known to be an important determinant of the
regional deposition pattern. Model predictions elucidated
that a high nasal deposition, possibly accompanied by sig-
nificant absorption, is expected following nose-only inhala-
tion studies (Supplementary Figure S6). Although nasal
absorption is absent for orally inhaled products in the clinic,
simulations suggest that nasal uptake reduces the degree
of lung-selectivity seen in preclinical models (Figure 3d,e).
Thus, accounting for this process might be important for
interpretation and translation of preclinical data, further
emphasizing the need of an integrated understanding of
formulation-specific, drug-specific, and system-specific
properties. If the technical challenges can be overcome,
experiments addressing the extent of nasal absorption after
nose-only inhalation would indeed be useful. Furthermore,
this example illustrates how the model lends itself for trans-
lation. As it relies on a physiological parametrization, trans-
lation from animal to man can be done by changing from
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nasal to oral inhalation and exchanging system-specific (rat
vs. human physiology) and formulation-specific parameters
(particle size, etc.). Human system-specific parameters are
provided in the Supplementary Material. This study dem-
onstrated the value of mechanistically describing the under-
lying processes of drug disposition in the lung to
understand how the delicate interactions among drug-
specific, formulation-specific, and system-specific properties
produce the final outcome of the system. The model
thereby provides a framework for rational drug design and
a facilitated translation from animal to man, which will be
instrumental to any drug discovery or development program
targeting the lung via the inhaled route.
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